TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2789428

Group type: EXPERIMENTAL
Intervention: Exogenous recombinant human EGF (hEGF) infusion (0.25-1.0 micrograms/kg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of pentagastrin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Modified sham feeding (MSF)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ordinary feeding
Number of subjects: 0

Group type: COMPARATOR
Intervention: Basal conditions
Number of subjects: 0
Study: 329662

Group type: EXPERIMENTAL
Intervention: Meclofenoxate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study: 31530611

Group type: EXPERIMENTAL
Intervention: DHA supplementation (4.4 g/day DHA orally)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo (equal fat supplement of vegetable oil)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: DHA supplementation
Number of subjects: 52
Study: 27520366

Group type: EXPERIMENTAL
Intervention: Organizational Process Improvement Intervention (OPII)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Delayed-start condition
Number of subjects: 21

Group type: COMPARATOR
Intervention: Early-start condition
Number of subjects: 21
Study: 26466913

Group type: EXPERIMENTAL
Intervention: Medical therapy plus psychotherapy (pyridoxine hydrochloride 40 mg daily for 3 weeks + mindfulness-based cognitive therapy in eight 50 min sessions over 3 weeks)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Medical therapy alone (pyridoxine hydrochloride 40 mg daily for 3 weeks)
Number of subjects: 86
Study: 25169035

Group type: EXPERIMENTAL
Intervention: Chewing ice
Number of subjects: 0

Group type: COMPARATOR
Intervention: Drinking tepid water
Number of subjects: 0
Study: 22320999

Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behavior therapy (ICBT)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Cognitive behavioral group therapy (CBGT)
Number of subjects: 126
Study: 20104970

Group type: EXPERIMENTAL
Intervention: 6th grade (or younger) cohort
Number of subjects: 3404

Group type: COMPARATOR
Intervention: 8th grade (or older) cohort
Number of subjects: 3404
Study: 17566394

Group type: EXPERIMENTAL
Intervention: salmeterol/fluticasone propionate (50/500 microg 2x/day)
Number of subjects: 6000
Study: 15687411

Group type: EXPERIMENTAL
Intervention: Comprehensive program of lifestyle modification
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Continued patient-therapist contact (in person or by telephone, mail, or e-mail)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High levels of physical activity and consumption of low-calorie, portion-controlled meals (including liquid meal replacements)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Macronutrient content (e.g., low-fat vs. low-carbohydrate diets)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Comprehensive weight loss control methods
Number of subjects: 0
Study: 11278151

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 38

Group type: COMPARATOR
Intervention: Other antipsychotic drugs (comparison group)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Risperidone
Number of subjects: 38

Group type: COMPARATOR
Intervention: Conventional antipsychotic drugs
Number of subjects: 38
Study: 10028794

Group type: EXPERIMENTAL
Intervention: Daily oral dosage of 6 mg/kg of elemental iron (Group A)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Intermittent oral dosage of 6 mg/kg of elemental iron, 3 days a week (Group B)
Number of subjects: 55
Study: 7986970

Group type: EXPERIMENTAL
Intervention: Clarithromycin 500 mg t.d.s. with meals plus amoxycillin 750 mg t.d.s. with meals for 10 days
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg each evening for 6 weeks (for ulcer healing)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Clarithromycin and amoxycillin therapy
Number of subjects: 29
Study: 2927630

Group type: EXPERIMENTAL
Intervention: Cued positions (light cue at the same location)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Within-field non-coincident cue-target pairs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cue-target asynchronies ranging from 0.2 to 1.5 sec
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cues remote from the target within the same lateral or altitudinal visual hemifield
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cues at 1 degree of visual angle from the midline and at 29 degrees from the cue
Number of subjects: 0
Study: 113217

Group type: EXPERIMENTAL
Intervention: Propranolol (non-selective beta blocker)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Atenolol (selective beta-1 blocker)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 30623736

Group type: EXPERIMENTAL
Intervention: Intracanal cryotherapy (20 mL sterile cold saline solution at 2.5 °C for 5 min)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (sterile saline solution at room temperature)
Number of subjects: 60
Study: 27323324

Group type: EXPERIMENTAL
Intervention: Radial extracorporeal shock wave therapy (rESWT) plus physical therapy
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham shock wave plus physical therapy
Number of subjects: 30
Study: 25444236

Group type: EXPERIMENTAL
Intervention: High-tech AAC systems (special smiles for special children material)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Low-tech AAC systems
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: High-tech AAC systems
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups (Low-tech and High-tech AAC systems)
Number of subjects: 60
Study: 23421363

Group type: EXPERIMENTAL
Intervention: Texas Implementation of Medication Algorithm (TIMA) for Bipolar Disorder
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 0
Study: 22117977

Group type: EXPERIMENTAL
Intervention: Modified submuscular transposition with Z‐lengthening of the pronator teres origin
Number of subjects: 278

Group type: COMPARATOR
Intervention: Subcutaneous transposition
Number of subjects: 278
Study: 19863304

Group type: EXPERIMENTAL
Intervention: Corticosteroid therapy
Number of subjects: 30
Study: 17680957

Group type: EXPERIMENTAL
Intervention: Leukoreduced RBC transfusions (LR)
Number of subjects: 1085

Group type: COMPARATOR
Intervention: Standard buffy-coat-depleted RBC transfusions (BCD)
Number of subjects: 1085
Study: 15299099

Group type: EXPERIMENTAL
Intervention: Group A (HSC infusion)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Group B (Control)
Number of subjects: 24
Study: 11023568

Group type: EXPERIMENTAL
Intervention: Transnasal endoscopy using a 5.3 mm fiberscope
Number of subjects: 160

Group type: COMPARATOR
Intervention: Transoral endoscopy using a standard upper endoscope
Number of subjects: 160
Study: 9096446

Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (LMWH)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (LMWH) continued for another 12 months
Number of subjects: 76

Group type: COMPARATOR
Intervention: Conventional heparin
Number of subjects: 76
Study: 8211369

Group type: EXPERIMENTAL
Intervention: Static lumbar traction
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Intermittent lumbar traction
Number of subjects: 100
Study: 3698519

Group type: EXPERIMENTAL
Intervention: Proximal nerve blockade
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Local beta-receptor blockade
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control subjects (normal cardiac performance)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: CHF patients
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Increase in local venous transmural pressure
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Decrease in forearm perfusion pressure
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Baseline FSVR and plasma concentrations of noradrenaline and adrenaline
Number of subjects: 9
Study: 4576562

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nandrolone decanoate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of cyclophosphamide and nandrolone decanoate
Number of subjects: 0
Study: 31688865

Group type: EXPERIMENTAL
Intervention: Intensive treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 0
Study: 30172964

Group type: EXPERIMENTAL
Intervention: Designated leadership
Number of subjects: 408

Group type: COMPARATOR
Intervention: Emergent leadership
Number of subjects: 408

Group type: COMPARATOR
Intervention: Smaller teams (3 rescuers)
Number of subjects: 408

Group type: EXPERIMENTAL
Intervention: Larger teams (6 rescuers)
Number of subjects: 408
Study: 27129426

Group type: EXPERIMENTAL
Intervention: High-dose trivalent inactivated influenza vaccine (HD TIV)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Standard-dose trivalent inactivated influenza vaccine (SD TIV)
Number of subjects: 85
Study: 25188774

Group type: EXPERIMENTAL
Intervention: Clonidine (150 μg) as an adjuvant to levobupivacaine (Chirocaine)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Levobupivacaine (Chirocaine) alone
Number of subjects: 120
Study: 22024920

Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol 160 μg/4.5 μg ten inhalations daily for 3 days via Turbuhaler®
Number of subjects: 25

Group type: COMPARATOR
Intervention: Terbutaline 0.4 mg ten inhalations daily for 3 days via Turbuhaler®
Number of subjects: 25
Study: 20228284

Group type: EXPERIMENTAL
Intervention: Unconscious processing (performing an unrelated distracter task)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conscious processing (consciously thinking about the information)
Number of subjects: 0
Study: 17666035

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 16
Study: 15682362

Group type: EXPERIMENTAL
Intervention: Reversible regional wall motion abnormalities (RWMAs) identified in 102 patients
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: Poststress RWMAs
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: Amount of ischemia
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: Combined model of prescan and perfusion data with poststress RWMAs
Number of subjects: 303
Study: 12088920

Group type: EXPERIMENTAL
Intervention: Recombinant human GH (rhGH) replacement
Number of subjects: 41
Study: 10205235

Group type: EXPERIMENTAL
Intervention: Dobutamine (up to 9 microg/kg body weight per minute)
Number of subjects: 13
Study: 7542966

Group type: EXPERIMENTAL
Intervention: Visual laser ablation of the prostate using the Urolase right-angle fiber
Number of subjects: 0

Group type: COMPARATOR
Intervention: Transurethral prostatectomy
Number of subjects: 0
Study: 2222941

Group type: EXPERIMENTAL
Intervention: Caffeinated coffee
Number of subjects: 12

Group type: COMPARATOR
Intervention: Decaffeinated coffee
Number of subjects: 12
Study: 361059

Group type: EXPERIMENTAL
Intervention: diflucortolone valerate 0.3% ointment
Number of subjects: 354

Group type: COMPARATOR
Intervention: clobetasol propionate 0.05% ointment
Number of subjects: 354
Study: 31917692

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI) in STEMI patients with CAA
Number of subjects: 8131

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI) in NSTEMI patients with CAA
Number of subjects: 8131

Group type: EXPERIMENTAL
Intervention: Overall PCI rate in patients with CAA
Number of subjects: 8131

Group type: COMPARATOR
Intervention: Revascularization trends in AMI patients with CAA
Number of subjects: 8131
Study: 31530081

Group type: EXPERIMENTAL
Intervention: Transforaminal lumbar interbody fusion (TLIF)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Instrumented posterolateral fusion (PLF)
Number of subjects: 100
Study: 28799710

Group type: EXPERIMENTAL
Intervention: Continuous N95 respirator use
Number of subjects: 3591

Group type: EXPERIMENTAL
Intervention: Targeted N95 respirator use
Number of subjects: 3591

Group type: EXPERIMENTAL
Intervention: Medical mask use
Number of subjects: 3591

Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 3591
Study: 25811263

Group type: EXPERIMENTAL
Intervention: Cervical total disc replacement (CTDR)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Anterior cervical discectomy and fusion (ACDF)
Number of subjects: 0
Study: 23830094

Group type: EXPERIMENTAL
Intervention: UMEC/VI 62.5/25 mcg
Number of subjects: 1532
Study: 20829308

Group type: EXPERIMENTAL
Intervention: Fluoxetine medication
Number of subjects: 0

Group type: COMPARATOR
Intervention: Short-term psychodynamic psychotherapy
Number of subjects: 0
Study: 19480657

Group type: EXPERIMENTAL
Intervention: Buspirone (30 mg p.o.)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Morphine (10 mg i.v.)
Number of subjects: 12
Study: 17666197

Group type: EXPERIMENTAL
Intervention: Angiotensin receptor blockers (ARBs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme (ACE) inhibitors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of telmisartan and ramipril
Number of subjects: 0

Group type: COMPARATOR
Intervention: Telmisartan
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ramipril
Number of subjects: 0
Study: 14574621

Group type: EXPERIMENTAL
Intervention: Fighting Spirit (Mental Adjustment to Cancer, MAC) in the Graz sample
Number of subjects: 424

Group type: EXPERIMENTAL
Intervention: Perceived Family Support (PFS) in the Jerusalem sample
Number of subjects: 424
Study: 11224753

Group type: EXPERIMENTAL
Intervention: MultiHance (gadobenate dimeglumine) at 0.1 mmol/kg
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: MultiHance (gadobenate dimeglumine) at 0.05 mmol/kg
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: MultiHance (gadobenate dimeglumine) cumulative doses
Number of subjects: 205

Group type: COMPARATOR
Intervention: Omniscan (gadodiamide) at 0.1 mmol/kg
Number of subjects: 205

Group type: COMPARATOR
Intervention: Omniscan (gadodiamide) at 0.3 mmol/kg
Number of subjects: 205
Study: 15102402

Group type: EXPERIMENTAL
Intervention: Stimulus duration of 400 ms
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Stimulus duration of 200 ms
Number of subjects: 12
Study: 8284093

Group type: EXPERIMENTAL
Intervention: Dexamethasone treatment at day 10 (n = 14)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group (no respiratory disease or recovered from respiratory distress syndrome, n = 10)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Dexamethasone treatment at day 16 (n = 13)
Number of subjects: 27
Study: 2892881

Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 6570

Group type: COMPARATOR
Intervention: Diuretics
Number of subjects: 6570
Study: 29283590

Group type: EXPERIMENTAL
Intervention: Pacing, Graded Activity, and Cognitive Behavioral Therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 28122622

Group type: EXPERIMENTAL
Intervention: SMS reminders
Number of subjects: 1677

Group type: COMPARATOR
Intervention: Control (standard care)
Number of subjects: 1677

Group type: EXPERIMENTAL
Intervention: Intervention (SMS reminders)
Number of subjects: 1677
Study: 25453534

Group type: EXPERIMENTAL
Intervention: Nesiritide therapy
Number of subjects: 811

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 811
Study: 23290142

Group type: EXPERIMENTAL
Intervention: Seromuscular tunnel anastomosis
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Split-cuff nipple reimplantation
Number of subjects: 62
Study: 21640782

Group type: EXPERIMENTAL
Intervention: Zolpidem 10mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Zolpidem 20mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 18586762

Group type: EXPERIMENTAL
Intervention: Intravenous C.E.R.A. administered once every 2 weeks (Q2W)
Number of subjects: 313

Group type: COMPARATOR
Intervention: Darbepoetin alfa (DA) administered once weekly (QW)
Number of subjects: 313
Study: 17139037

Group type: EXPERIMENTAL
Intervention: Group cognitive-behavioural therapy
Number of subjects: 113

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 113
Study: 12919163

Group type: EXPERIMENTAL
Intervention: Hydrocortisone 10 mg with breakfast and 5 mg with lunch (Schedule 1)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Hydrocortisone with the addition of 5 mg with the evening meal (Schedule 2)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Dexamethasone 0.1 mg/15 kg body weight given per day with breakfast only (Schedule 3)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Dexamethasone (Schedule 3)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Hydrocortisone schedules (1 and 2)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: All three treatment schedules
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: All three replacement schedules
Number of subjects: 26
Study: 10488714

Group type: EXPERIMENTAL
Intervention: Microsatellite instability (MSI) assessment using 29 fluorescence-labeled microsatellite markers
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Loss of heterozygosity assessment in 29 markers
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Assessment of replication errors in coding regions of specific genes
Number of subjects: 38
Study: 8909439

Group type: EXPERIMENTAL
Intervention: Peptide T 6 mg/day
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study: 1857947

Group type: EXPERIMENTAL
Intervention: Glycine solution
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Glucose (WHO) solution
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Polycose solution
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Rice-flour solution
Number of subjects: 7
Study: 6354523

Group type: EXPERIMENTAL
Intervention: Percutaneous dihydrotestosterone (DHT) 125 mg twice daily
Number of subjects: 43

Group type: COMPARATOR
Intervention: DHT therapy (group B)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo (group C)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: DHT treatment (group A)
Number of subjects: 43
Study: 30873752

Group type: EXPERIMENTAL
Intervention: Obesity prevention intervention (OP) - 14-session phone-based
Number of subjects: 421

Group type: COMPARATOR
Intervention: Safety and injury prevention contact control (CC)
Number of subjects: 421
Study: 29149143

Group type: EXPERIMENTAL
Intervention: TAP block with 20 mL per side of 0.25% bupivacaine plus 2 mL magnesium sulphate 10% (200 mg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: TAP block with 20 mL per side of 0.25% bupivacaine
Number of subjects: 60
Study: 26141307

Group type: EXPERIMENTAL
Intervention: SPIRIT intervention (Sharing Patient's Illness Representations to Increase Trust)
Number of subjects: 420

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 420
Study: 23601452

Group type: EXPERIMENTAL
Intervention: METABO
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 21108699

Group type: EXPERIMENTAL
Intervention: peginterferon (PEG‐IFN) alfa‐2a and ribavirin (RBV)
Number of subjects: 3070

Group type: EXPERIMENTAL
Intervention: peginterferon (PEG‐IFN) alfa‐2b and ribavirin (RBV)
Number of subjects: 3070
Study: 19845267

Group type: EXPERIMENTAL
Intervention: Preoperative endoanal ultrasonography
Number of subjects: 214

Group type: COMPARATOR
Intervention: No preoperative endoanal ultrasonography
Number of subjects: 214
Study: 16706948

Group type: EXPERIMENTAL
Intervention: Safe Sea (topical jellyfish sting inhibitor)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Coppertone (placebo control)
Number of subjects: 82
Study: 15006886

Group type: EXPERIMENTAL
Intervention: Octreotide
Number of subjects: 230

Group type: COMPARATOR
Intervention: Control
Number of subjects: 230
Study: 11896407

Group type: EXPERIMENTAL
Intervention: RRV-TV (lower-titer formulation: 4 x 10(4) pfu/dose)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: RRV-TV
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9539588

Group type: EXPERIMENTAL
Intervention: Laryngeal Mask Airway (LMA)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Endotracheal Tube (ETT)
Number of subjects: 82
Study: 8697047

Group type: EXPERIMENTAL
Intervention: Fluoxetine treatment
Number of subjects: 1441

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 1441
Study: 1699861

Group type: EXPERIMENTAL
Intervention: Lymphoblastoid interferon therapy
Number of subjects: 30
Study: 380609

Group type: EXPERIMENTAL
Intervention: Mepivacaine (250 mg i.v. infusion)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Prilocaine (250 mg i.v. infusion)
Number of subjects: 5
Study: 6303793

Group type: EXPERIMENTAL
Intervention: Combination chemotherapy (CAMP-L: cyclophosphamide, doxorubicin, methotrexate, procarbazine, leucovorin)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Sequential chemotherapy (methotrexate/leucovorin followed by cyclophosphamide/doxorubicin at progression)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Combination chemotherapy
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Partial response
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Stable disease
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: No response
Number of subjects: 56
Study: 29224638

Group type: EXPERIMENTAL
Intervention: Bridge therapy with dalteparin 100 IU/kg twice daily
Number of subjects: 1813

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1813

Group type: EXPERIMENTAL
Intervention: Perioperative aspirin use
Number of subjects: 1813

Group type: EXPERIMENTAL
Intervention: Postprocedure international normalized ratio >3.0
Number of subjects: 1813

Group type: EXPERIMENTAL
Intervention: High-bleeding risk procedures
Number of subjects: 1813

Group type: EXPERIMENTAL
Intervention: History of renal disease
Number of subjects: 1813

Group type: EXPERIMENTAL
Intervention: Time-dependent risk in the first 10 days postprocedure
Number of subjects: 1813
Study: 27838534

Group type: EXPERIMENTAL
Intervention: Health-Promoting Lifestyle (HPL) education
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 64
Study: 25432270

Group type: EXPERIMENTAL
Intervention: Individualized performance feedback (n=46)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Practice-only condition (weekly writing practice; n=39)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Instructional control condition (n=48)
Number of subjects: 133
Study: 22428764

Group type: EXPERIMENTAL
Intervention: Red wine (Pinot Noir)
Number of subjects: 120

Group type: COMPARATOR
Intervention: White wine (Chardonnay-Pinot)
Number of subjects: 120